Abstract: Provided are a supported catalyst including: a support body which is formed by a catalyst composition being supported by a carrier, in which the catalyst composition contains an oxide of copper, and the carrier contains ?Al2O3.?B2O3 (? and ? each represent a positive number); and a hydrogen production method for producing hydrogen from ammonia, including: an ammonia combustion step of reacting ammonia with oxygen in the presence of the supported catalyst; and an ammonia decomposition step of decomposing the ammonia into hydrogen and nitrogen by utilizing heat generated by the reaction between the ammonia and the oxygen.

Abstract: Various embodiments relate to a compound of the formula (I): wherein X, X1, R1—R4 and R7 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I), or a pharmaceutical compositions comprising compounds of the formula (I), to a patient in need thereof.

Abstract: A method for controlling the kinetics of a cultured cell includes: a culture step of culturing a cell adhered to the surface of a base material including titanium oxide having an anatase structure on the surface; an irradiation step of irradiating the surface with light in a wavelength range in which the titanium oxide exhibits photocatalytic activity during culture of the cell; and a control step of controlling the kinetics of the cell by controlling the irradiation amount of the light to the surface. The wavelength range may be 400 nm or less.

Abstract: The present invention provides a mucosal immunomodulator comprising, as an active ingredient, at least one selected from the group consisting of compounds represented by the following formula (1), compounds represented by the following formula (2) and compounds represented by the following formula (3), and salts thereof.

Abstract: To provide a magnesium alloy having high incombustibility, high strength and high ductility together. A magnesium alloy including Ca in an amount of “a” atomic %, Al in an amount of “b” atomic % and a residue of Mg, including (Mg, Al)2Ca in an amount of “c” volume %, wherein “a”, “b” and “c” satisfy the following equations (1) to (4), and having the (Mg, Al)2Ca dispersed therein. 3?a?7??(1) 4.5?b?12??(2) 1.2?b/a?3.

Abstract: Provided is a needle removal operation cover with which a user can safely perform an injection needle removal operation even when a needle tip is directly inserted into the needle removal operation cover, and with which the user can remove the injection needle without requiring a wrist twisting motion.

Abstract: The nanoparticle assembly includes nanoparticles having an average primary particle size of 60 nm or less, and the nanoparticle assembly has a diameter of more than 500 nm and 5 ?m or less.

Abstract: Disclosed is a magnesium alloy material having excellent tensile strength and favorable ductility. Therefore, the magnesium alloy sheet material formed by rolling a magnesium alloy having a long period stacking order phase crystallized at the time of casting includes in a case where a sheet-thickness traverse section of an alloy structure is observed at a substantially right angle to the longitudinal direction by a scanning electron microscope, a structure mainly composed of the long period stacking order phase, in which, at least two or more ?Mg phases having thickness in the observed section of 0.5 ?m or less are laminated in a layered manner with the sheet-shape long period stacking order phase.

Abstract: The present invention provides black particles having high electrical insulation properties, high blackness in a visible light region, and excellent dispersibility, and a method for producing the black particles. The present invention relates to black particles containing amorphous carbon, the amorphous carbon being derived from carbon contained in an oxazine resin, the black particles having a specific gravity of 1.8 g/cm3 or less, a zeta potential of ?70 to +80 mV, an average total light reflectance measured at a wavelength of 400 to 800 nm of 5% or less, and a peak intensity ratio between G band and D band as determined from a Raman spectrum of 1.2 or more.

Abstract: A magnesium alloy having high strength and high ductility and in which at least one of corrosion resistance and flame resistance is enhanced, or a method of manufacturing the same. The magnesium alloy contains an atomic % of Ca and b atomic % of Al, totally contains k atomic % of at least one element selected from a group consisting of Mn, Zr, Ag, Y and Nd, has a composition in which a remaining part is formed of Mg and contains c volume % of (Mg, Al)2Ca, a, b, c and k satisfying formulae (1) to (4) and (21) below. The (Mg, Al)2Ca is dispersed and the at least one element is an element that enhances at least one of corrosion resistance and flame resistance: (1) 3?a?7, (2) 4.5?b?12, (3) 1.2?b/a?3.0, (4) 10?c?35, (21) 0<k?0.3.

Abstract: A method produces a composite of a polymer and tungstic acid and/or molybdic acid; and the composite obtained by the method has high transparency and a desired refractive index. This composite contains tungstic acid and/or molybdic acid and a polymer that has a number average molecular weight of 1,000-10,000,000 and an ether bond and/or an ester bond. The content of tungstic acid and/or molybdic acid in the composite is 0.01-95% by weight.

Abstract: Provided is a biodegradable polymer coating stent effective in delaying the damage of physical properties (particularly radial force) of a core structure. The stent includes a core structure of a bioabsorbable material (e.g., Mg), a first coating layer of a first polymer with biodegradability, and a second coating layer of a second polymer with biodegradability, wherein the first coating layer covers the whole surface of the core structure; the second coating layer covers a part or the whole surface of the first coating layer; the first polymer has a glass transition point of lower than 37° C.; and the second polymer has a glass transition point of 47° C. or higher.

Abstract: The purpose of the present invention is to provide a process or method that can be utilized when deriving a three-dimensional structure of a kidney from pluripotent stem cells such as ES cells or iPS cells. The differentiation inducing method is characterized by culturing pluripotent cells with the following three steps, in order: (a) a step of culturing an embryoid body induced from the pluripotent stem cells in medium containing Bmp4 and a high-concentration (concentration A) Wnt agonist; (b) a step of culturing the embryoid body in medium which contains activin, Bmp4, retinoic acid and a middle-concentration (concentration B) Wnt agonist; and (c) a step of culturing the embryoid body in medium containing Fgf9 and a low-concentration (concentration C) Wnt agonist (herein, the Wnt agonist concentrations is concentration A>concentration B>concentration C).

Abstract: Various embodiments relate to a compound of the formula (I): wherein X, X1, R1-R4 and R7 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I), or a pharmaceutical compositions comprising compounds of the formula (I), to a patient in need thereof.

Abstract: An object of the present invention is to provide a method of producing a myeloid blood cell possessing a proliferative capability. According to the present invention, provided is a method of producing a myeloid blood cell possessing a proliferative capability, including forcedly expressing (A) a cMYC gene, and (B) at least one gene selected from the group consisting of a BMI1 gene, an EZH2 gene, an MDM2 gene, an MDM4 gene, and an HIF1A gene in a myeloid blood cell.

Abstract: An electrolytic treatment method in which a predetermined treatment is performed using treatment subject ions contained in a treatment liquid, the method including: an electrode positioning step for positioning a direct electrode and a counter electrode so as to sandwich the treatment liquid, and positioning an indirect electrode for forming an electric field in the treatment liquid; a treatment subject ion migration step for applying a voltage to the indirect electrode and thereby moving the treatment subject ions in the treatment liquid to the counter electrode side; and a treatment subject ion redox step for applying a voltage between the direct electrode and the counter electrode and thereby oxidizing or reducing the treatment subject ions which have migrated to the counter electrode side.

Abstract: A method for producing a model animal which has a desired lifetime, and in which a predetermined biological reaction can be induced, and a model animal are provided. The present invention produces a first individual in which a gene of interest is heterozygously deficient using a first ES cell from a non-human mammalian animal. Meanwhile, a fragment containing a homologous gene that has homology to the gene of interest is made, a second ES cell constituted so that a predetermined region on X chromosome of the animal can be substituted is used, and the fragment is introduced into the second ES cell to generate a substituted ES cell in which the predetermined region has been substituted with the fragment. A second individual is produced using the substituted ES cell. The first individual and the second individual are mated with each other to produce a model animal.

Abstract: The purpose of the present invention is to provide a method and a culture medium which are capable of efficiently inducing the differentiation of pluripotent stem cells such as ES cells and iPS cells into desired cells by a simple means. The differentiation of pluripotent stem cells can be induced by culturing mammal-derived pluripotent stem cells in a differentiation culture medium that does not contain at least one amino acid selected from the group consisting of methionine, leucine, cysteine, tyrosine and arginine. Also provided is a differentiation-inducing culture medium which does not contain at least one amino acid selected from the group consisting of methionine, leucine, cysteine, tyrosine and arginine.

Abstract: Provided are a method for preparing a mammalian ovum or embryo in which zona pellucida has been thinned or eliminated, and a method for fertilization using the mammalian ovum prepared by the aforementioned method. The resulting mammalian ovum or embryo is capable of realizing an improved fertilization rate and development rate when used for in vitro fertilization, transplantation of a fertilized ovum, or for preparation of an embryo in the early stages of development used in the production of a genetically modified animal.

Abstract: An object of the invention is to provide a thin film manufacturing device which further reduces a load on a substrate. Provided is a thin film manufacturing device for forming a thin film on a substrate by supplying a mist of a solution including a thin-film forming material to the substrate, characterized in that the device includes: a plasma generation unit including a first electrode and a second electrode disposed closer to one surface of the substrate, which generates plasma between the first electrode and the second electrode; and a mist supply unit which passes the mist between the first electrode and the second electrode and supplies the mist to the substrate.